Curis (NASDAQ:CRIS) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Curis (NASDAQ:CRIS) issued its quarterly earnings data on Thursday. The biotechnology company reported ($1.94) earnings per share for the quarter, topping the consensus estimate of ($2.01) by $0.07, Zacks reports.

Curis Stock Down 3.1%

NASDAQ CRIS traded down $0.02 on Thursday, reaching $0.57. The company had a trading volume of 424,225 shares, compared to its average volume of 1,241,869. The stock has a market capitalization of $2.35 million, a P/E ratio of -0.04 and a beta of 3.28. The company’s fifty day moving average is $0.80 and its 200 day moving average is $8.39. Curis has a 52-week low of $0.33 and a 52-week high of $28.40.

Wall Street Analyst Weigh In

CRIS has been the topic of a number of recent analyst reports. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 22nd. HC Wainwright restated a “buy” rating on shares of Curis in a research report on Monday, August 17th. Zacks Research raised Curis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $43.00.

About Curis

Curis, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation. Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.